Omeros stock drops as short-seller takes aim

Omeros' stock has fallen about 19 percent after investment adviser FourWorld Capital Management forecast a sharp drop in revenue after Medicare reimbursement ended for its only drug on the market.

Source: bizjournals.com Health Care:Biotechnology headlines - February 14, 2018 Category: Biotechnology Authors: Casey Coombs Source Type: news